Search results for OpenEvidence
AI & Enterprise
AI reshapes enterprise IT adoption playbook, a16z analysis finds
Many surveys suggest corporate AI adoption often stalls at the pilot stage, including an MIT finding that 95 percent of pilot projects do not move into production. Andreessen Horowitz, citing internal data and conversations with executives, disputes that view. Its analysis focuses on where enterprises use AI and where returns are clear, excluding consumer-focused companies. It says 29 percent of Fortune 500 firms and 19 percent of Global 2000 firms are paying customers of leading AI startups and are running AI in production.
AI & Enterprise
Healthcare AI startup OpenEvidence raises $250 million, valued at $12 billion
Healthcare AI startup OpenEvidence raised $250 million in funding, boosting its valuation to $12 billion, SiliconANGLE reported on Jan. 21 local time. Thrive Capital and DST Global participated. OpenEvidence said its valuation has risen more than tenfold since its first funding round last year. The company provides a ChatGPT-style research tool for clinicians that searches medical journals and suggests diagnosis and treatment options. It also supports medical education and plans additional apps.
AI & Enterprise
AI sales concentration deepens as AI-native firms seek to diversify beyond subscriptions
Revenue at AI-native companies selling AI models or services is rising, but sales are heavily concentrated. OpenAI and Anthropic account for nearly 85 percent of annualised revenue among the top 10, and the top 10 reach 94 percent combined. Some apps have passed annualised revenue milestones, and ad-based models are emerging. OpenEvidence sells chatbot ads to doctors and drugmakers. Despite growth, uncertainty persists as many firms remain loss-making and face competition from model providers.